摘要
目的:通过新辅助化疗提高三阴性乳腺癌(TNBC)手术切除的近期和远期疗效并比较两种不同方案新辅助化疗的治疗效果。方法:128例局部晚期TNBC患者分为两组,A组采取ET(吡柔比星联合多西他赛)方案,B组采取GP(顺铂联合吉西他滨)方案进行新辅助化疗,观察化疗后病理反应及其与远期生存的关系。结果:ET组有效率为88.7%,GP组为82.0%。两组5年总生存率和5年无病生存率(DFS)分别为75.4%、71.4%和85.3%、58.9%。结论:TNBC对紫杉联合蒽环类(ET组)较顺铂联合吉西他滨的(GP组)新辅助化疗更敏感,更易获cCR、pCR。
OBJECTIVE： To comparing the efficacy of two different protocal of neoadjuvant chemotherapy on triple negative breast cancer（TNBC）. METHODS： A total of 128 cases of locally advanced breast cancer patients were divided into A and B groups, and all with pathologically diagnosis of TNBC by immunohistoehemis＇try. A was given pirarubicin combining Docetaxel（ET）, and B was given cisplatin combining Gecitabine（GP）. After neoadjuvant chemotherapy, pathological reaction and long term follow up were observed. RESULTS： The efficiency of the ET group was 88.7%, and GP group was 82.0%. The 5 year survival rate and disease-free survival （DFS） of Group A were 75.4%, and 85.3% ; Group B is 71.4% and 58.9%, respectively There was significant difference between the two groups. CONCLUSION： The results show that anthracycline combining taxane （ET group） have more sensitive than cisplatin combining gemcitabine （GP group） to TNBC for neoadjuvant chemotherapy, more accessible cCR, pCR.
出处
《中华肿瘤防治杂志》
CAS
2009年第23期1872-1874,共3页
Chinese Journal of Cancer Prevention and Treatment
关键词
乳腺肿瘤/药物疗法
药物疗法
联合
预后
breast neoplasms/drug therapy
drug therapy, combination
prgnosis
